[Current Aspects of Definition and Diagnosis of Pulmonary Hypertension]

T J Lange1, M Borst2, R Ewert3

  • 1Uniklinik Regensburg, Klinik für Innere Medizin II, Bereich Pneumologie, Regensburg.

Insights

The 6th World Symposium on Pulmonary Hypertension lowered the diagnostic threshold for pulmonary hypertension (PH) to >20 mmHg and included pulmonary vascular resistance. This impacts PH diagnosis and management.

Area of Science:

  • Cardiology
  • Pulmonology
  • Medical Diagnostics

Background:

  • The 6th World Symposium on Pulmonary Hypertension (WSPH) convened in 2018 to review advancements in PH over the preceding five years.
  • Key findings were published, introducing significant revisions to the diagnostic criteria for PH.

Purpose of the Study:

  • To discuss the rationale and implications of the revised PH definition proposed by the WSPH.
  • To provide an updated overview of diagnostic and prognostic methods for PH.

Main Methods:

  • Review of scientific progress presented at the 6th WSPH.
  • Analysis of the proposed changes to the PH definition, including diagnostic thresholds and criteria.
  • Overview of current non-invasive and invasive diagnostic techniques, including exercise testing.

Main Results:

  • The WSPH recommended lowering the diagnostic threshold for PH from ≥25 mmHg to >20 mmHg mean pulmonary arterial pressure.
  • Pulmonary vascular resistance was incorporated into the definition of PH, emphasizing cardiac output measurement.
  • The article discusses the potential consequences of these definition changes.

Conclusions:

  • The revised definition of PH signifies a major shift in diagnostic criteria.
  • Understanding these changes is crucial for accurate diagnosis, differential diagnosis, and prognosis of PH.
  • A comprehensive approach integrating updated definitions and diagnostic methods is essential for managing pulmonary hypertension.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
472
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
385
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
484
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
398
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
358
Measurement of Blood Pressure01:17

Measurement of Blood Pressure

Assessing blood pressure is a standard procedure executed in virtually all medical environments. The method utilized today was established over a hundred years ago by an innovative Russian doctor, Dr. Nikolai Korotkoff. The soft ticking noise, known as Korotkoff sounds, heard while taking blood pressure readings results from turbulent blood flow within the vessels. The apparatus required for this procedure includes a sphygmomanometer, a blood pressure cuff attached to a gauge, and a...
2.4K